Categories AlphaGraphs, Earnings, Retail
Earnings preview: Hormel Foods likely to face challenges in Q3
Hormel Foods Corporation (NYSE: HRL) is scheduled to report third quarter 2019 earnings results on Thursday, August 22, before the market opens. Analysts expect the company to report earnings of $0.37 per share on revenue of $2.31 billion.
In the third quarter, the Grocery Products and Refrigerated Foods divisions are likely to see their momentum continue, helped by the Herdez, Wholly Guacamole and Hormel Bacon products.
The retail sales declines which hurt the turkey business last quarter could continue in the to-be-reported quarter as well. However, the company has been taking measures to drive sales growth in its turkey division and it remains to be seen how far these steps have been effective.
Hormel is also likely to struggle with high input costs and unstable tariffs impacting its pork business. The African swine fever in China negatively affected the company’s pork business last quarter leading Hormel to lower its guidance for full year 2019.
Hormel used its proceeds from the CytoSport sale to pay down debt and build its cash position. The company plans to use the cash to drive growth through strategic investments like acquisitions and capacity expansion projects.
Also see: Hormel Foods Q2 2019 Earnings Conference Call Transcript
In the second quarter of 2019, Hormel beat earnings estimates with a 4.5% increase in adjusted EPS to $0.46. Net sales inched up 0.6% to $2.34 billion.
Last quarter, Hormel lowered its fiscal 2019 net sales outlook to a range of $9.50 billion to $10 billion from the prior range of $9.70 billion to $10.20 billion, and its earnings guidance to a range of $1.71 to $1.85 per share from the previous range of $1.77 to $1.91 per share. The revised earnings guidance range was based on input cost increases and a forecast for volatile domestic pork prices in the second half of fiscal 2019.
Shares of Hormel have dropped 2.6% so far this year and 1% in the past one month. The company has an average price target of $41.50.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on